Low-degree trisomy 21 mosaicism promotes early-onset Alzheimer disease.

Nuebling, Georg S; Prix, Catharina; Brendel, Matthias; Beyer, Leonie; Wlasich, Elisabeth; Loosli, Sandra V; Barthel, Henryk; Sabri, Osama; Bartenstein, Peter; Vöglein, Jonathan; Danek, Adrian; Rominger, Axel; Edbauer, Dieter; Haass, Christian; Levin, Johannes (2021). Low-degree trisomy 21 mosaicism promotes early-onset Alzheimer disease. Neurobiology of aging, 103, 147.e1-147.e5. Elsevier 10.1016/j.neurobiolaging.2021.02.021

[img] Text
1-s2.0-S0197458021000762-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB) | Request a copy

Trisomy-21 mosaicism (mT21) with subclinical intellectual development disorder or physical phenotype has very rarely been associated with early-onset cognitive decline. Notably, early-onset Alzheimer's disease (EOAD) patients' family histories frequently suggest genetic causes other than autosomal-dominant APP/PSEN-1/2 mutations. We present an EOAD patient in his late fifties newly diagnosed with low-degree mT21 (13%/21% blood lymphocytes/ectodermal cells). We applied fluorescence in-situ hybridization to confirm a diagnosis of mT21. Multimodal positron-emission-tomography applying 18F-fluodesoxyglucose (metabolism), 18F-florbetaben (amyloid-β deposits) and 18F-PI-2620 (tau-deposits) tracers was used to confirm a diagnosis of EOAD according to the ATN-criteria of AD. Initial PET-studies revealed marked cerebral amyloid-β- and tau-pathology and parietotemporal hypometabolism, confirming EOAD according to the ATN-criteria of AD. A marked cognitive decline was accompanied by an increase in tau pathology in follow-up studies. This is the first case demonstrating that a low-degree APP gene-dose increase suffices to cause EOAD with prominent amyloid-β/tau pathology.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Radiology, Neuroradiology and Nuclear Medicine (DRNN) > Clinic of Nuclear Medicine

UniBE Contributor:

Rominger, Axel Oliver

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0197-4580

Publisher:

Elsevier

Language:

English

Submitter:

Daria Vogelsang

Date Deposited:

19 Jan 2022 16:54

Last Modified:

19 Jan 2022 16:54

Publisher DOI:

10.1016/j.neurobiolaging.2021.02.021

PubMed ID:

33789815

Uncontrolled Keywords:

Alzheimer disease Amyloid Neurogenetics PI-2620 Positron emission tomography Tau

BORIS DOI:

10.48350/163977

URI:

https://boris.unibe.ch/id/eprint/163977

Actions (login required)

Edit item Edit item
Provide Feedback